Stanford University, Eiger deal

Stanford University granted Eiger exclusive rights to Exendin (9-39) to treat post-bariatric surgical hypoglycemia. The competitive antagonist of glucagon-like peptide-1 receptor ( GLP-1R; GLP1R) h...